News 2023-03-25
Porton Released 2022 CSR Report
Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report since IPO. This report demonstrates the company's ideas and achievements in fulfilling social responsibility from aspects such as "improving corporate governance", "providing high-quality services", "empowering employee development", "practicing green development", and "participating in community co-development".
Portonisalways committed to sustainable development,adopting a development model that balances economic benefits with gover-nance, environment,and social welfare, in order tocontinuously enhance the company'sriskresistanceandsustainable business capabilities.
Currency:RMB
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities